{"id":"https://openalex.org/W2008219232","doi":"https://doi.org/10.1158/1538-7445.am2011-4486","title":"Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer","display_name":"Abstract 4486: INK128, a novel TORC1/2 inhibitor with potent oral antitumor activity in preclinical models of renal cancer","publication_year":2011,"publication_date":"2011-04-01","ids":{"openalex":"https://openalex.org/W2008219232","doi":"https://doi.org/10.1158/1538-7445.am2011-4486","mag":"2008219232"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2011-4486","doi":"https://doi.org/10.1158/1538-7445.am2011-4486","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2011-4486","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5086539759","display_name":"Shunyou Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Shunyou Wang","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043173903","display_name":"Katti Jessen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katti Jessen","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087682958","display_name":"Linda V. Kessler","orcid":"https://orcid.org/0000-0002-8677-3252","observed_orcids":["https://orcid.org/0000-0002-8677-3252"]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Linda Kessler","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054293865","display_name":"Jeff M. Kucharski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeff Kucharski","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000245618","display_name":"Lucy Lan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lucy Lan","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101440832","display_name":"Xin Guo","orcid":"https://orcid.org/0000-0002-8211-994X","observed_orcids":["https://orcid.org/0000-0002-8211-994X"]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xin Guo","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051502319","display_name":"Jocelyn Staunton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jocelyn Staunton","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105666887","display_name":"Marikka Elia","orcid":"https://orcid.org/0000-0002-4224-0761","observed_orcids":["https://orcid.org/0000-0002-4224-0761"]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marikka Elia","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Josh Stewart","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Josh Stewart","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066979115","display_name":"Levan Darjania","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Levan Darjania","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101826192","display_name":"Lian\u2010Sheng Li","orcid":"https://orcid.org/0000-0002-8187-2876","observed_orcids":["https://orcid.org/0000-0002-8187-2876"]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liansheng Li","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081239927","display_name":"Katrina Chan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Katrina Chan","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111870335","display_name":"Mike Martin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mike Martin","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109426168","display_name":"Pingda Ren","orcid":"https://orcid.org/0000-0002-4232-5271","observed_orcids":["https://orcid.org/0000-0002-4232-5271"]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pingda Ren","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059938229","display_name":"Christian Rommel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christian Rommel","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5063328758","display_name":"Yi Liu","orcid":"https://orcid.org/0000-0003-0169-1125","observed_orcids":["https://orcid.org/0000-0003-0169-1125","https://orcid.org/0000-0002-4998-5547","https://orcid.org/0009-0009-4812-6968"]},"institutions":[{"id":"https://openalex.org/I1343180700","display_name":"Intel (United States)","ror":"https://ror.org/01ek73717","country_code":"US","type":"company","lineage":["https://openalex.org/I1343180700"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yi Liu","raw_affiliation_strings":["1Intellikine, Inc., La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Intellikine, Inc., La Jolla, CA","institution_ids":["https://openalex.org/I1343180700"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343180700"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"71","issue":"8_Supplement","first_page":"4486","last_page":"4486"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9883000254631042,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9883000254631042,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.010300000198185444,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10631","display_name":"Cancer, Hypoxia, and Metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ink128","display_name":"INK128","score":0.9959999918937683},{"id":"https://openalex.org/keywords/mtor-inhibitors","display_name":"mTOR inhibitors","score":0.7919999957084656},{"id":"https://openalex.org/keywords/torc1","display_name":"TORC1","score":0.8220000267028809},{"id":"https://openalex.org/keywords/torc2","display_name":"TORC2","score":1.0},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/oral-antitumor-activity","display_name":"oral antitumor activity","score":0.7300000190734863},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.9210000038146973},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9409999847412109},{"id":"https://openalex.org/keywords/rapamycin","display_name":"rapamycin","score":0.7889999747276306},{"id":"https://openalex.org/keywords/akt-phosphorylation","display_name":"Akt phosphorylation","score":0.8799999952316284},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.8220000267028809},{"id":"https://openalex.org/keywords/g1-cell-cycle-arrest","display_name":"G1 cell cycle arrest","score":0.8379999995231628}],"concepts":[{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.6939005255699158},{"id":"https://openalex.org/C75217442","wikidata":"https://www.wikidata.org/wiki/Q423650","display_name":"Protein kinase B","level":3,"score":0.6317638158798218},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5579019784927368},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5355695486068726},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.5150032043457031},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4902072548866272},{"id":"https://openalex.org/C2776820818","wikidata":"https://www.wikidata.org/wiki/Q7699074","display_name":"Temsirolimus","level":5,"score":0.44718044996261597},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.43958455324172974},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3919840455055237},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2776471972465515},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.25110068917274475},{"id":"https://openalex.org/C11960822","wikidata":"https://www.wikidata.org/wiki/Q242736","display_name":"Phosphorylation","level":2,"score":0.21668675541877747},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.16343095898628235},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.14452621340751648},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1207023561000824},{"id":"https://openalex.org/C183713625","wikidata":"https://www.wikidata.org/wiki/Q5282002","display_name":"Discovery and development of mTOR inhibitors","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2011-4486","doi":"https://doi.org/10.1158/1538-7445.am2011-4486","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2011-4486","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2061822535","https://openalex.org/W2089617164","https://openalex.org/W2125589120","https://openalex.org/W2069745248","https://openalex.org/W2051688670","https://openalex.org/W2326363825","https://openalex.org/W2069723796","https://openalex.org/W1965797794","https://openalex.org/W2080541934","https://openalex.org/W2333039840"],"abstract_inverted_index":{"Abstract":[0],"Objective:":[1],"Preclinical":[2],"characterization":[3],"and":[4,9,30,40,52,66,78,95,101,121,123,149,158,181,198,210,226,249,256,272,294,323,355],"evaluation":[5],"of":[6,17,46,85,99,105,119,127,135,153,165,179,185,191,194,206,212,244,259,269,306,309,335,346,348,364,375,380],"INK128":[7,144,175,201,241,271,310,327,349],"alone":[8],"in":[10,15,62,132,145,147,150,196,199,217,234],"combination":[11,308],"with":[12,87,93,311,361],"anti-angiogenic":[13],"agents":[14,167],"models":[16,152],"renal":[18,137,154,336],"cell":[19,38,47,56,63,138,155,208,214,281,337],"carcinoma.":[20],"Background:":[21],"mTOR":[22,86,112],"kinase":[23,83],"comprises":[24],"two":[25],"distinct":[26],"multi-protein":[27],"complexes,":[28],"TORC1":[29,42,116,122],"TORC2,":[31],"which":[32],"together":[33],"regulate":[34],"processes":[35],"critical":[36],"for":[37,110,113,332,384],"growth":[39,276,298],"survival.":[41],"regulates":[43,59],"protein":[44],"translation":[45],"cycle":[48,215],"regulators,":[49],"angiogenic":[50],"factors,":[51],"factors":[53],"that":[54,266],"control":[55],"motility.":[57,67],"TORC2":[58,124,195],"pathways":[60,130],"involved":[61],"metabolism,":[64],"survival":[65],"Through":[68],"rational":[69],"drug":[70],"design":[71],"we":[72],"have":[73,142],"identified":[74],"INK128,":[75,223],"a":[76,329],"potent":[77,204],"selective":[79],"small":[80],"molecule,":[81],"active-site":[82],"inhibitor":[84],"excellent":[88],"drug-like":[89],"properties.":[90],"Activity":[91],"seen":[92],"temsirolimus":[94],"everolimus,":[96],"pharmaceutical":[97],"derivatives":[98],"rapamycin":[100,251,273],"allosteric":[102],"partial":[103],"inhibitors":[104],"TORC1,":[106,186],"provide":[107],"clinical":[108],"proof-of-concept":[109],"targeting":[111,320,340],"cancer":[114],"therapy.":[115],"is":[117,350],"upstream":[118],"HIF1/2":[120],"are":[125,267],"downstream":[126,183,193,268],"the":[128,133,235,238,307,324,333,344,376,381],"VEGF":[129],"implicated":[131],"tumorigenesis":[134],"metastatic":[136],"carcinoma":[139,156,338],"(RCC).":[140],"We":[141],"investigated":[143],"preclinical":[146],"vitro":[148,197],"vivo":[151],"(RCC)":[157],"compared":[159],"its":[160],"activity":[161,305],"to":[162,170],"other":[163],"standard":[164,363],"care":[166,365],"commonly":[168],"used":[169],"treat":[171],"this":[172],"disease.":[173],"Results:":[174],"selectively":[176],"inhibited":[177],"phosphorylation":[178,190,243,255,258],"S6":[180,248,254],"4EBP1,":[182],"substrates":[184],"as":[187,189],"well":[188],"AKT":[192],"vivo.":[200],"demonstrated":[202],"very":[203],"inhibition":[205],"tumor":[207,221,275,280,297,302,317,321],"proliferation":[209],"induction":[211],"G1":[213],"arrest":[216],"vitro.":[218],"In":[219,291],"mouse":[220],"models,":[222],"rapamycin,":[224],"avastin":[225,295,314],"sorafenib":[227,261,293,312],"displayed":[228],"anti-tumor":[229,239],"efficacy;":[230],"however,":[231],"they":[232],"differ":[233],"mechanisms":[236],"underlying":[237],"activity.":[240],"inhibits":[242,253],"AKT,":[245],"PRAS40,":[246],"NDRG1,":[247],"4EBP1;":[250],"only":[252],"induces":[257],"AKT;":[260],"activates":[262],"several":[263],"pathway":[264],"components":[265],"TORC1/2.":[270],"suppressed":[274,296],"by":[277,299,319,339],"directly":[278],"inhibiting":[279,301],"proliferation;":[282],"however":[283],"neither":[284],"had":[285],"much":[286],"impact":[287],"on":[288],"tumor-associated":[289],"angiogenesis.":[290,303],"contrast,":[292],"potently":[300],"The":[304],"or":[313],"yielded":[315],"sustained":[316],"regression":[318],"cells":[322],"microenvironment.":[325],"Conclusion:":[326],"offers":[328],"novel":[330],"approach":[331],"treatment":[334],"TORC1/2":[341],"signaling.":[342],"Additionally,":[343],"mechanism":[345],"action":[347],"different":[351],"than":[352],"current":[353,362],"therapies":[354],"may":[356],"not":[357],"display":[358],"cross":[359],"resistance":[360],"agents.":[366],"Citation":[367],"Format:":[368],"{Authors}.":[369],"{Abstract":[370],"title}":[371],"[abstract].":[372],"In:":[373],"Proceedings":[374],"102nd":[377],"Annual":[378],"Meeting":[379],"American":[382],"Association":[383],"Cancer":[385,395],"Research;":[386],"2011":[387],"Apr":[388],"2-6;":[389],"Orlando,":[390],"FL.":[391],"Philadelphia":[392],"(PA):":[393],"AACR;":[394],"Res":[396],"2011;71(8":[397],"Suppl):Abstract":[398],"nr":[399],"4486.":[400],"doi:10.1158/1538-7445.AM2011-4486":[401]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-29T09:56:32.521200","created_date":"2016-06-24T00:00:00"}